Peter Emtage, Santa Ana Bio CEO (Versant)
March 10, 2023 07:30 AM ESTUpdated 07:46 AM
Financing
Startups

Ver­san­t's new im­munol­o­gy biotech San­ta Ana Bio snags Se­ries A with GV, TPG part­ners on board

Kyle LaHucik

Senior Reporter

Pro­lif­ic biotech in­vestor Ver­sant Ven­tures is brew­ing an­oth­er start­up, this time im­munol­o­gy play­er San­ta Ana Bio, whose board in­cludes part­ners from GV and TPG. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times